Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The investigators aim to develop a model to predict the response to chemotherapy by DNA methylation of preoperative biopsy specimens to identify the chemotherapy ineffective group.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak przełyku
- •Pacjent poddany chemioterapii
- •Pierwsza w życiu chemioterapia
- •Świadoma zgoda na udział w badaniu
✗ Disqualifies
- •Niemożliwość pobrania próbki tkanki przed operacją
- •Niemożliwość oceny stanu pacjenta 2 miesiące po chemioterapii
- •Współwystępowanie innych nowotworów
Simplified criteria — AI translation
Trial details
- Minimum age
- 20 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Yamanashi Universiy
Chūō, Japan
Trial contact
Ajay Goel, PhD
Koichi Takiguchi, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.